10/24
08:08 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
10/15
12:31 pm
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
10/15
12:31 pm
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
10/15
12:14 pm
jspr
Rating for JSPR
Low
Report
Rating for JSPR
10/15
12:14 pm
jspr
Rating for JSPR
Low
Report
Rating for JSPR
10/15
08:47 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
9/27
11:05 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
9/27
11:05 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $70.00 price target on the stock.
9/27
10:53 am
jspr
Rating for JSPR
Low
Report
Rating for JSPR
9/27
10:53 am
jspr
Rating for JSPR
Low
Report
Rating for JSPR
9/9
02:14 pm
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/9
01:10 pm
jspr
Rating for JSPR
Low
Report
Rating for JSPR
9/9
08:01 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $70.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $70.00 price target on the stock.
9/9
08:01 am
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $70.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $70.00 price target on the stock.
9/9
05:59 am
jspr
Rating for JSPR
Low
Report
Rating for JSPR
9/9
05:59 am
jspr
Rating for JSPR
Low
Report
Rating for JSPR
8/26
01:02 pm
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Evercore ISI. They now have a $65.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Evercore ISI. They now have a $65.00 price target on the stock.
8/26
01:02 pm
jspr
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Evercore ISI. They now have a $65.00 price target on the stock.
Medium
Report
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its "outperform" rating re-affirmed by analysts at Evercore ISI. They now have a $65.00 price target on the stock.
8/26
12:32 pm
jspr
Rating for JSPR
Medium
Report
Rating for JSPR